Skip to main content

Table 3 Logistic regression analysis on background factors influencing pulse oximetry below 94% 24-h after infusion of casirivimab-imdevimab

From: Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors

  

Univariate Analysis

Multivariate Analysis

Factor

Cutoff

OR

CI, lower

CI, upper

P

OR

CI, lower

CI, upper

P

Age

55

0.692

0.261

1.837

0.46

    

Male

 

1.582

0.588

4.259

0.364

    

Smoking

 

0.794

0.297

2.122

0.646

    

Body Mass Index

23

3.467

1.152

10.431

0.027*

3.145

0.958

10.326

0.059

Symptomatic

3 days

2.338

0.874

6.255

0.091

    

CT Bilateral

 

7.368

2.501

21.705

< 0.001*

5.544

1.599

19.228

0.007*

PreTemp

37

0.672

0.243

1.856

0.443

    

PreOx

96%

2.706

0.686

10.669

0.155

    

White Blood Cell

4300

0.992

0.373

2.638

0.988

    

Neutrophil

64%

1.106

0.416

2.936

0.840

    

Lymphocyte

24%

0.692

0.261

1.837

0.460

    

C-Reactive Protein

0.53 mg/dl

3.286

1.092

9.888

0.034*

1.543

0.402

5.923

0.528

Total Bilirubin

0.55 mg/dl

1.134

0.222

5.796

0.880

    

Creatinine

0.7 mg/dl

2.125

0.646

6.987

0.215

    

Platelet

180 × 103

0.912

0.346

2.405

0.853

    

2-Time Vaccination

 

0.502

0.104

2.425

0.391

    
  1. CI, 95% confidence interval; CT Bilateral, computed tomography showing bilateral ground glass attenuation; PreTemp, pre-infusion body temperature; PreOx, pre-infusion pulse oximetry; *, P < 0.05
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us